penciclovir (denavir) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Penciclovir (DENAVIR®) is a synthetic acyclic guanine derivative with antiviral activity, mainly used to treat infections from herpes simplex virus (HSV) types 1 and 2. In cells infected with HSV-1 or HSV-2, the viral thymidine kinase phosphorylates penciclovir to a monophosphate form that, in turn, is converted by cellular kinases to the active form penciclovir triphosphate. Biochemical studies demonstrate that penciclovir triphosphate inhibits HSV polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited. Famciclovir (FAMVIR®) is a prodrug form of penciclovir with improved oral bioavailability.   NCATS

Chemistry

  • SMILES: Nc1nc(O)c2ncn(CCC(CO)CO)c2n1
  • InChIKey: JNTOCHDNEULJHD-UHFFFAOYSA-N
  • Mol. Mass: 253.26
  • ALogP: -0.9
  • ChEMBL Molecules:
    penciclovir  
    penciclovir sodium  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$92.3680 - $156.2449
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

9-[2-hydroxy-1-(hydroxymethyl)-ethoxymethyl]guanine | 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine | 9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine | 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine | 9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine | brl 39123 | brl-39123 | denavir | fenistil | novartis brand of penciclovir | pcv | pe2 | penciclovir | penciclovir, monosodium salt | penciclovir, monosodium salt, monohydrate | penciclovir sodium | penciclovirum | penciclovir visfarm | sb-ch brand of penciclovir | vectavir | visfarm brand of penciclovir

Organizations (6)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Herpes Labialis

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Herpes Labialis ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue